Chemical Market Reporter - AGALSIDASE BETA.(Genzyme General)(Brief Article)
January 1, 2001 -- FDA has completed its review of the biologics license application for Genzyme General's Fabrazyme (agalsidase beta), an investigational enzyme...
Business Wire - Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
October 15, 2008 -- CAMBRIDGE, Mass. -- Genzyme Corporation (Nasdaq: GENZ) announced today that the company has begun enrollment in a world-wide post-marketing clinical...
Pharma Marketletter - Genzyme's 2nd-qtr revenues jump 58%
July 19, 2004 -- USA-based Genzyme Corp has posted a 58% leap in second-quarter 2004 sales to $549.6 million versus $347.7 million for the like, year-earlier period,...
Chemical Market Reporter - Trankaryotic Therapies Inc. (Active Pharmaceutical Ingredient Watch).(Brief Article)
August 4, 2003 -- TRANSKARYOTIC THERAPIES Inc. (TKT) has received European Commission approval for its Cambridge, Mass., plant for the commercial manufacture of...
Drug Cost Management Report - Genzyme Corp. reported 30% revenue growth in its second quarter of 2003, which it attributed primarily to product sales - Brief Article
July 25, 2003 -- * Genzyme Corp. reported 30% revenue growth in its second quarter of 2003, which it attributed primarily to product sales. Sales of Renagel...
FDA Consumer - First treatment for Fabry's disease - Updates - Brief Article
July 1, 2003 -- The FDA has approved Fabrazyme (agalsidase beta), the first treatment for people with Fabry's disease. This serious genetic metabolic disorder...
Chemical Market Reporter - Genyzme wins FDA nod. (News in Brief).(Genzyme Corp., U.S. Food and Drug Administration approval for marketing Fabrazyme )(Brief Article)
April 28, 2003 -- Genzyme Corp. has been granted Food and Drug Administration (FDA) approval to market Fabrazyme (agalsidase beta). The drug will be the first...
Pharma Marketletter - Update: Genzyme gets US go-ahead for Fabrazyme.
May 5, 2003 -- The US Food and Drug Administration has granted marketing approval to Genzyme for its Fabrazyme (agalsidase beta) enzyme replacement therapy for...
Pharma Marketletter - Genzyme gets US go-ahead for Fabry drug Fabrazyme.
May 5, 2003 -- The US Food and Drug Administration has granted marketing approval to Genzyme for its Fabrazyme (agalsidase beta) enzyme replacement therapy for...
Chemical Market Reporter - Genzyme General. (Active Pharmaceutical Ingredient Watch).(Posted fourth quarter revenues up 12% to $298 mil)(Brief Article)
March 10, 2003 -- GENZYME GENERAL posted fourth quarter revenues up 12 percent to $298 million. Excluding special items and amortization, net income rose 17 percent...
